Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plonmarlimab - NovaBridge Biosciences

Next Previous
Drug Profile

Plonmarlimab - NovaBridge Biosciences

Alternative Names: Anti-GM-CSF monoclonal antibody - NovaBridge Biosciences; TJ 003234; TJ-003234RAR101; TJM-2

Latest Information Update: 10 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator I-MAB Biopharma
  • Developer NovaBridge Biosciences
  • Class Antirheumatics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophagocytic lymphohistiocytosis
  • Phase II/III Cytokine release syndrome
  • No development reported Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 05 Mar 2026 TJ Biopharma plans a phase II trial for Gouty arthritis (Treatment experienced) in China (IV, Infusion) (NCT07453004)
  • 21 Nov 2025 Phase-III clinical trials in Haemophagocytic lymphohistiocytosis (In adolescents, In adults, In the elderly, Treatment-experienced) in China (IV) (NCT07208058)
  • 30 Oct 2025 I-MAB Biopharma is now called NovaBridge Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top